3.6 Adequate renal and hepatic function (serum creatinine <2.5 mg/dl and 
bilirubin < 1.7 mg/dl). 
3.7 At least four weeks since any prior radiation therapy, immunotherapy, or 
chemotherapy (six weeks for nitrosoureas) , and full recovery from such 
treatment . 
3.8 The ability to give written informed consent. 
3.9 Age —18 years. 
3.10 No history of other concurrent malignancies except basal cell carcinoma 
or carcinoma in situ of the cervix. 
3.11 No systemic steroids for at least one week prior to treatment. 
3.12 No intracranial or multiple hepatic metastases. 
3.13 Availability of fresh or frozen autologous tumor suitable for lymphocyte 
proliferation studies. 
4.0 Exclusion Criteria 
The following conditions/situations will render patients ineligible for this 
study: 
4.1 Serious intercurrent medical illness, to include significant cardiac 
disease, angina pectoris, or myocardial infarction within the previous six 
months . 
4.2 Active infection, including urinary tract infection. 
4.3 Active intracranial metastases. Previously resected intracranial disease 
and or previously irradiated intracranial metastases which have been stable 
for 4 weeks are eligible. 
4.4 Multiple hepatic metastases (tumor replacing 50% or more of liver 
parenchyma) . 
4.5 Pregnant or lactating women. 
4.6 Patients requiring systemic corticosteroids. 
5.0 Concurrent Therapy 
The following therapies are prohibited while patients are being treated on 
this protocol: radiation therapy, chemotherapy, corticosteroids (except as 
administered for life-threatening circumstances), or other immunizations. 
Recombinant DNA Research, Volume 18 
[353] 
